Crohn's Disease Symptoms?

What Are the Symptoms of Crohn's Disease?

Persistent diarrhea (loose, watery, or frequent bowel movements), crampy abdominal pain, fever, and, at times, rectal bleeding: These are the hallmark symptoms of Crohn's disease, but they vary from person to person and may change over time. Loss of appetite and subsequent weight loss also may occur. However, the disease is not always limited to the GI tract; it can also affect the joints, eyes, skin, and liver. Fatigue is another common complaint. Children who have Crohn's disease may suffer delayed growth and sexual development.

Some patients may develop tears (fissures) in the lining of the anus, which may cause pain and bleeding, especially during bowel movements. Inflammation may also cause a fistula to develop. A fistula is a tunnel that leads from one loop of intestine to another, or that connects the intestine to the bladder, vagina, or skin. Fistulas occur most commonly around the anal area. If this complication arises, you may notice drainage of mucus, pus, or stool from this opening.

Symptoms may range from mild to severe. Because Crohn's is a chronic disease, patients will go through periods in which the disease flares up, is active, and causes symptoms. These episodes are followed by times of remission -- periods in which symptoms disappear or decrease and good health returns. In general, though, people with Crohn's disease lead full, active, and productive lives.

Types of Crohn's Disease and Associated Symptoms

The symptoms and complications of Crohn's disease differ, depending on what part of the intestinal tract is inflamed. That's why it is important for you to know which part of your intestine is affected by Crohn's disease. Your doctor may also refer to your illness by various names based on the principal area involved. The following are five types of Crohn's disease, together with their presenting symptoms:

. Ileocolitis: The most common form of Crohn's, affecting the ileum and colon. Symptoms include diarrhea and cramping or pain in the right lower part or middle of the abdomen. Often accompanied by significant weight loss.

. Ileitis: Affects the ileum. Symptoms same as ileocolitis. Complications may include fistulas or inflammatory abscess in right lower quadrant of abdomen.

. Gastroduodenal Crohn's disease: Affects the stomach and duodenum (the first part of the small intestine). Symptoms include loss of appetite, weight loss, and nausea. Vomiting may indicate that narrowed segments of the bowel are obstructed.

. Jejunoileitis: Produces patchy areas of inflammation in the jejunum (upper half of the small intestine. Symptoms include abdominal pain (ranging from mild to intense) and cramps following meals, as well as diarrhea. Fistulas may form.

. Crohn's (granulomatous) colitis: Affects the colon only. Symptoms include diarrhea, rectal bleeding, and disease around the anus (abscess, fistulas, ulcers). Skin lesions and joint pains are more common in this form of Crohn's than in others.

• Musculoskeletal Center Wins $2.2 Million For Drug Safety

The University of Alabama at Birmingham (UAB) Center for Education and Research on Therapeutics (CERTs) has won a $2.2 million federal grant to study the risks and benefits of a newer class of medicines called biologics. These are genetically engineered therapies that target the immune system of patients who have rheumatoid arthritis, Crohn's disease, psoriasis and other autoimmune disorders.
• Crohn's Disease Surgeries Make Steady Advances

Thousands of Americans suffering from the chronic inflammatory bowel condition known as Crohn's disease are leading longer, healthier lives due to innovative new surgeries, according to experts at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
• Prometheus Presents New Clinical Insights Into Diagnosis Of Crohn's Disease In Children From Analysis Of PROMETHEUS(R) IBD Serology 7 Test Results

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced new findings regarding the correlation between serologic markers and the diagnostic predictions of children with Crohn's disease following an analysis of PROMETHEUS(R) IBD Serology 7 test results.
• Adalimumab May Reduce Health-Care Costs For Crohn's Disease Patients

Additional study shows further research needed on 5-ASA's chemopreventative role in ulcerative colitis Inflammatory bowel disease (IBD) is a term that refers to both ulcerative colitis (UC) and Crohn's disease (CD). IBD occurs most frequently in people in their late teens and twenties. There have been cases in children as young as two years old and in older adults in their seventies and eighties; men and women have an equal chance of getting the disease.
• A Faster Test For The Food Protein That Triggers Celiac Disease - Analytical Chemistry Journal

Researchers in Spain and the United Kingdom are reporting development of a faster test for identifying the food protein that triggers celiac disease, a difficult-to-diagnose digestive disease involving the inability to digest protein called gluten that occurs in wheat, oats, rye, and barley. The finding could help millions of people avoid diarrhea, bloating, and other symptoms that occur when they unknowingly eat foods containing gluten.
• Philips' Intelligent Pill Targets Drug Development And Treatment For Digestive Tract Diseases

At this week's opening of the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition (Atlanta, USA, November 16-20, 2008) Philips Research will announce its new intelligent pill technology "iPill", targeted at assisting drug development and enabling new therapies for debilitating and life-threatening digestive tract disorders such as Crohn's disease, colitis and colon cancer.
• Abbott's HUMIRA® (adalimumab) Data Shows Fistula Healing For Up To Three Years In Patients With Moderate To Severe Crohn's Disease

New data showed that Abbott's (NYSE: ABT) HUMIRA® (adalimumab) provided long-term treatment of fistulas, with more than half of patients with moderate to severe Crohn's disease experiencing fistula healing at three years, according to clinical research presented today at the United European Gastroenterology Week (UEGW) congress in Vienna.
• Newly Discovered Immune Cell May Help Those With Crohn's And Colitis

The tonsils and lymphoid tissues in the intestinal tract that help protect the body from external pathogens are the home base of a rare immune cell newly identified by researchers at Washington University School of Medicine in St. Louis. The researchers indicate that the immune cells could have a therapeutic role in inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis.
• Crohn's Disease - Neovacs Begins A Phase I/II Clinical Trial With Candidate TNFα-kinoid, First Phase I/II Human Study Of A Kinoid

Neovacs, a leading biotechnology company in the development of anti-cytokine and anti-protein viral regulation therapeutic vaccines to treat certain cancers and inflammatory diseases, announced that it had begun a phase I/II clinical study at three study centres in South Africa with the candidate TNFα-kinoid, a therapeutic vaccine for the treatment of TNFα dependent auto-immune diseases such as rheumatoid arthritis, Crohn's disease and psoriasis.
• Remicade(R) (Infliximab) Is More Likely To Induce Steroid-Free Remission And Mucosal Healing Compared With Azathioprine

Data presented today at the United European Gastroenterology Week Congress (UEGW) show that a significantly greater proportion of patients with moderate to severe Crohn's disease experienced steroid-free remission and mucosal healing when receiving Remicade(R) (infliximab), either in combination with azathioprine or as monotherapy, compared to patients receiving azathioprine alone.
• HUMIRA(R) (adalimumab) Data Shows Fistula Healing For Up To 3 Years In Patients With Moderate To Severe Crohn's Disease

New data showed that Abbott's HUMIRA® (adalimumab) provided long-term treatment of fistulas, with more than half of patients with moderate to severe Crohn's disease experiencing fistula healing at three years, according to clinical research presented today at the United European Gastroenterology Week (UEGW) congress in Vienna.
• New Information Guides Available For Patients Diagnosed With Inflammatory Bowel Disease

To help those with inflammatory bowel disease (IBD) be better informed and involved in managing their disease, the European Foundation of Crohn's & Ulcerative Colitis Associations (EFCCA) has launched a new series of guides titled "Life and IBD". For over one million people across Europe who have it, IBD can be an overwhelming experience with new physicians, medications and terminology.
• CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation In Crohn's Disease Patients

Data from two studies presented this week by UCB at the American College of Gastroenterology (ACG) Annual Meeting demonstrate that CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF alpha (Tumor Necrosis Factor alpha) - provides sustained improvement in symptoms with stable dosing for adult patients suffering from moderate to severe Crohn's disease (CD).
• Mayo Clinic Collaborates To Advance Crohn's Treatment

A study led by Mayo Clinic has found that infliximab (Remicade®) administered alone (monotherapy) or in combination with azathioprine is a more effective treatment for patients with moderate to severe Crohn's disease than azathioprine alone. These findings were presented at the 2008 American College of Gastroenterology (ACG) Annual Meeting. Crohn's disease is an inflammatory disorder of the gastrointestinal tract that affects an estimated 500,000 people in the United States.
• CIMZIA(R) (certolizumab Pegol) Reduces Intestinal Lesions And Induces Endoscopic Improvement In Crohn's Patients

UCB presented data from a large, prospective study investigating endoscopic improvement in Crohn's disease (CD) with a biologic compound.
• New Findings Show Efficacy Of REMICADE(R) Compared With Azathioprine In Treatment Of Crohn's Disease According To First-of-its Kind Study

Data presented for the first time from the Phase 3b Study of Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy (SONIC) may provide new insights into the approach to care of patients with moderate to severe Crohn's disease.
• Form Of Crohn's Disease Traced To Disabled Gut Cells

Scientists report online in Nature that they have linked the health of specialized gut immune cells to a gene associated with Crohn's disease, an often debilitating and increasingly prevalent inflammatory bowel disorder. The link to immune cells intrigued researchers at Washington University School of Medicine in St. Louis because they and others believe Crohn's disease is caused by misdirected immune responses in the intestine that damage gut tissue.
• Ore Pharmaceuticals Begins Clinical Trial Of GL1001 - Inflammatory Bowel Disease Drug Candidate's First Multiple Dose Trial

Ore Pharmaceuticals Inc. (NASDAQ: ORXE) announced today that it has initiated dosing subjects with GL1001, the Company's lead drug candidate, in a multiple ascending dose clinical trial. GL1001, the first clinical-stage inhibitor of the ACE2 enzyme, is an orally administered small molecule that has decreased several disease activity measures in in vivo models of inflammatory bowel disease (IBD) and gastritis.
• Philadelphia Inquirer Series Examines Difficulties Of Obtaining Affordable Coverage For People With Chronic Health Conditions

The Philadelphia Inquirer on Tuesday -- in the second article of a series titled "Falling Through: Casualties of the Health Insurance Crisis" -- examined how people with chronic illnesses face challenges in obtaining affordable health coverage.
• In Crohn's Disease A Case Of False Positive Octreoscan

Neuroendocrine tumors, such as carcinoid tumors, overexpress somatostatin receptors in their membranes. Octreotide is an analogue whose molecule is a shortened version of somatostatin's with a high affinity for these receptors. The labelled form of octreotide is able to be imaged in scans (Octreoscan) and, therefore, pathological conditions overexpressing somatostatin receptors are easily recognized in this technique.
• Early Onset Gene For Inflammatory Bowel Diseases Identified

A study of Crohn's disease and ulcerative colitis in children has identified a gene that influences whether children get these diseases early in life, and points to a potential new target for treatment. The findings of the international team that performed the study were published online this week by the journal Nature Genetics.
• Life Begins At 40 For NHS Occupational Therapist Who Suffered From Crohn's Disease

Cardiff has the highest incidence of Crohn's Disease in the UK. The University Hospital of Wales is conducting research into the condition with eminent gastroenterologist Dr Hawthorne of Cardiff and Vale NHS Trust who himself is part of a national study. Researchers are analysing data from the last 25 years in an attempt to explain what could cause the condition to be more prevalent in Cardiff isolating such factors as diet, bacterial infection and genetic impact.
• Pathogen That Causes Disease In Cattle Also Associated With Crohn's Disease - Research Urgently Needed To Evaluate Potential Risks To Humans

People with Crohn's disease (CD) are seven-fold more likely to have in their gut tissues the bacterium that causes a digestive-tract disease in cattle called Johne's disease. The role this bacterium may or may not play in causing CD is a top research priority, according to a new report released by the American Academy of Microbiology.
• Pill Cam SB Could Help Doctors Treat Children With Crohn's

According to a study released on July 9, 2008 in the Journal of Pediatric Gastroenterology and Nutrition, PillCam capsule endoscopy in the small intestines may improve Crohn's Disease treatment regimens in children by assisting in appropriate classification of inflammatory bowel diseases. Inflammatory bowel diseases (IBD) are a set of chronic inflammatory diseases of the intestinal tract.
• Drug For Treatment Of Inflammatory Bowel Disease - New Formula Allows For Greater Absorption, Fewer Doses

Physician-scientists from NewYork-Presbyterian/Weill Cornell, involved in clinical trials for a new drug for those who suffer from inflammatory bowel disease (IBD), say it is the best option among available drugs. Gaizo is a reformulation of the active ingredient 5-ASA in currently available drugs. However, the researchers found that 99 percent of the active ingredient in the new pill is released in the colon compared to only 70 percent in other common IBD drugs. Dr.

crohn disease symptoms